The Valley Desk

NCT03972657 · Interventional trial

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

Overall registry status Recruiting

Phase 1 · Phase 2

Conditions Clear Cell Renal Cell Carcinoma (ccRCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov